Linghang Pharmaceutical Biotechnology plans to acquire 100% equity of Conflux to enter the blockchain field and expand its diversified business
ChainCatcher news, Hong Kong-listed company Pioneer Pharma Biotechnology Limited (00399) announced the signing of a memorandum of understanding, planning to acquire 100% equity of a target company, provided that the target company completes the acquisition of Conflux blockchain-related assets. The acquisition consideration will be paid in cash, company shares, or convertible bonds, with the specific amount to be determined. The memorandum of understanding is valid for 12 months, during which the seller shall not negotiate with third parties regarding the equity of the target company. This move aims to help Pioneer Pharma expand its blockchain technology business, achieve business diversification, and seek new profit growth points. The transaction is subject to the signing of a formal agreement before it can be finalized.
ChainCatcher reminds readers to view blockchain rationally, enhance risk awareness, and be cautious of various virtual token issuances and speculations. All content on this site is solely market information or related party opinions, and does not constitute any form of investment advice. If you find sensitive information in the content, please click , and we will handle it promptly.






